{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:38:04Z","timestamp":1790797084354,"version":"4.1.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Following the promising pre-marketing placebo-controlled randomized clinical trials of fremanezumab, post-marketing studies are necessary to verify efficacy and tolerability in various real-world settings. The present study assessed real-world efficacy and safety of fremanezumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A 3-month, single-center, prospective, observation study of adults with chronic migraine who were treated with monthly subcutaneous injections of 225\u2009mg fremanezumab in Denmark. The primary outcome was defined as proportion of patients who achieved \u226530% reduction in monthly migraine days (MMDs) from baseline to weeks 9\u201312. Among secondary outcomes were \u226550 and \u226575% responder rates and the proportion of patients reporting adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 91 patients with chronic migraine were enrolled and received at least one dose of fremanezumab of whom 89 patients (98%) completed the 3-months treatment period. At baseline, the mean (SD) number of monthly headache days was 24.3\u2009\u00b1\u20095.8 and mean number of MMDs was 18.5\u2009\u00b1\u20097.4. The number of patients who achieved \u226530% reduction in MMDs from baseline to weeks 9\u201312 was 58 (65%), while 45 (51%) and 21 (24%) had \u226550 and 75% reduction in MMD, respectively. Twenty-one patients (23%) reported adverse event, in which the most common were constipation (4.4%), fatigue (4.4%) and dizziness (3.3%). No serious adverse events were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In adult chronic migraine patients with previous failure of conventional oral migraine preventives, fremanezumab was found to be effective and well-tolerated.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1226591","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T01:13:07Z","timestamp":1691716387000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Real-world efficacy and tolerability of fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, observational study"],"prefix":"10.3389","volume":"14","author":[{"given":"Christopher Kjaer","family":"Cullum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basit Ali","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thien Phu","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal Mohammad","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The international classification of headache disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-021-01279-7","article-title":"Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study","volume":"22","author":"Ashina","year":"2021","journal-title":"J Headache Pain"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/0333102411398400","article-title":"Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review","volume":"31","author":"Lant\u00e9ri-Minet","year":"2011","journal-title":"Cephalalgia"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/14656566.2022.2088281","article-title":"Advances in pharmacotherapy for the prophylactic treatment of resistant and refractory migraine","volume":"23","author":"Fitzek","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013 2022 update","volume":"23","author":"Sacco","year":"2022","journal-title":"J Headache Pain"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","article-title":"Long- term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study","volume":"95","author":"Goadsby","year":"2020","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of Fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","article-title":"Guidelines of the international headache society for controlled trials of preventive treatment of chronic migraine in adults","volume":"38","author":"Tassorelli","year":"2018","journal-title":"Cephalalgia"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s10194-022-01431-x","article-title":"FRIEND-study group. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12- week, multicenter, real-life, cohort study (the FRIEND study)","volume":"23","author":"Barbanti","year":"2022","journal-title":"J Headache Pain"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2217\/pmt-2021-0015","article-title":"Effectiveness of fremanezumab for preventive treatment of migraine: the observational pearl study","volume":"29","author":"Ashina","year":"2022","journal-title":"Eur J Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.3390\/jcm12093218","article-title":"Predictors of response to Fremanezumab in migraine patients with at least three previous preventive failures: post hoc analysis of a prospective, multicenter, real-world Greek registry","volume":"12","author":"Argyriou","year":"2023","journal-title":"J Clin Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s10194-023-01561-w","article-title":"Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FREIND2 study","volume":"24","author":"Barbanti","year":"2023","journal-title":"J Headache Pain"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s10194-023-01593-2","article-title":"Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the finesse study","volume":"24","author":"Straube","year":"2023","journal-title":"J Headache Pain"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1226591\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T01:13:12Z","timestamp":1691716392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1226591\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":15,"alternative-id":["10.3389\/fneur.2023.1226591"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1226591","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]},"article-number":"1226591"}}